clinical trial · NCT07199465
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 40
Cytomegalovirus ProphylaxisLetermovir
brief summary
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it
started
Mar 30, 2026
primary completion
Apr 14, 2028
completion
May 19, 2028
last updated
Apr 20, 2026
official title
A Phase 1, Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Letermovir in Pediatric Kidney Transplant (KT) Recipients Less Than 18 Years of Age and Weighing Less Than 40 Kilograms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol